Pyxus' indirect Canadian subsidiary receives ACMPR cannabis cultivation license from Health Canada

Tuesday, October 2, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

MORRISVILLE, N.C., Oct. 2, 2018 /PRNewswire/ -- Pyxus International Inc. (NYSE: PYX) is pleased to announce that its indirect

Canadian subsidiary, Goldleaf Pharm Inc., has received its Access to Cannabis for Medical Purposes Regulations (ACMPR) cultivation license from Health Canada. The license, awarded September 28, 2018, permits Goldleaf Pharm
to begin cultivating medicinal cannabis at its Simcoe, Ontario facility.

"This is an important step, and an exciting time, for us at Goldleaf Pharm," said Larry Huszczo, Goldleaf Pharm's co-founder. "We have a state of the art 20,000 square foot indoor growing facility, and recently acquired 20-acres of adjacent property, giving us the ability to expand to more than 700,000 square feet of production space to cultivate cannabis. I am very proud of our team, which has worked diligently to meet Health Canada's requirements."

Goldleaf Pharm is a subsidiary of Pyxus' indirect Canadian subsidiary, FIGR Inc. This latest milestone follows shortly after an announcement by FIGR that its Charlottetown subsidiary, Canada's Island Garden Inc. (CIG), received approval from Health Canada for the sale of medicinal cannabis oils. CIG previously announced a supply agreement with the province of Prince Edward Island for 1,000 kilograms/kilogram equivalent of cannabis products.

With this development, FIGR's two subsidiaries are now both licensed to produce medicinal cannabis in Canada. This also places FIGR's subsidiaries in a position to produce cannabis for adult recreational use in Canada after October 17, 2018, when it is set to become legal in that country.

About Pyxus International, Inc.Pyxus International Inc. is a global agricultural company with 145 years' experience delivering value-added products and services to businesses and customers. Driven by a united purpose—to transform people's lives, so that together we can grow a better world—Pyxus International, its subsidiaries and affiliates, are trusted providers of responsibly sourced, independently verified, sustainable and traceable products and ingredients. For more information, visit www.pyxusintl.com.

 

              

 

Cision View original content:http://www.prnewswire.com/news-releases/pyxus-indirect-canadian-subsidiary-receives-acmpr-cannabis-cultivation-license-from-health-canada-300722515.html

SOURCE Pyxus International, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store